Sigyn Therapeutics, Inc.
SIGY· OTC
SIGYSigyn Therapeutics, Inc.
Filed May 14, 2024 · 10-Q · 44 days after period end · 0001493152-24-019221
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Net Income | -$758.09K | -$1.34M | -$678.05K | -$461.68K |
| EPS Diluted | -$0.62 | -$1.39 | — | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed May 14, 2024 · 44 d after period end
